## Abstract Insulin is known to cause an increase in endothelin‐1 (ET‐1) receptors in vascular smooth muscle cells (SMCs), but the effect of insulin‐like growth factor 1 (IGF‐1) on ET‐1 receptor expression is not known. We therefore carried out the present study to determine the effect of IGF‐1 on
Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities
✍ Scribed by K. E. Bornfeldt; R. A. Gidlöf; A. Wasteson; M. Lake; A. Skottner; H. J. Arnqvist
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 683 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0012-186X
No coin nor oath required. For personal study only.
✦ Synopsis
Binding and growth promoting effects of insulin, insulin analogues modified in the B chain, proinsulin, insulin-like growth factor-I and -II were studied in cultured rat aortic smooth muscle cells. Specific binding of ~2~I-insulin was 0.9 + 0.2% of total ~25I-insulin added, and the ICs0-value was estimated to 8.9 pmol/1. The insulin analogue B10 Asp tended to be more potent than insulin in displacing ~25I-insulin, B28 Asp was equipotent, B9 Asp/B27 Glu was approximately 100 times less potent and insulin-like growth factor-I more than 1000 times less potent than insulin. Specific binding of ~I-insulin-like growth factor-I after 4 h incubation at 10 ~ was five times higher than the specific binding of insulin (4.4_+ 0.4% of total ~25I-insulin-like growth factor-I added), and the ICs0-value was 0.3 nmol/1. Insulin was approximately 500 times less potent than insulin-like growth factor-I in displacing '~I-insulin-like growth factor-I. The insulin analogue B10 Asp was slightly more potent and analogue B28 Asp was equipotent with insulin. Analogue B9 Asp/B27 Glu was ten times less potent and proinsulin was more than ten times less potent than insulin. The order of potency was similar for 3H-thymidine incorporation into DNA: insulin-like growth factor-I > B10 Asp > insulin-like growth factor-II > insulin _> B28 Asp > B9 Asp/B27 Glu > proinsulin. The maximal effect of insulin-like growth factor-I on 3H-thymidine incorporation was 71 _+ 16% higher than the maximal effect of insulin. The maximal effect of insulin-like growth factor-II was at least as high as the effect of insulin-like growth factor-I. Furthermore, the maximal effect of B10 Asp was 62 + 10% higher than the maximal effect of insulin. Insulin-like growth factor-I and B10 Asp tended to increase cell number more than insulin. In conclusion, this study shows that insulin analogues interact with different potencies with receptors for insulin and insulin-like growth factor-I in vascular smooth muscle cells and that insulin-like growth factors and the insulin analogue B10 Asp have more pronounced growth effects than insulin. Substitution of the amino acid Asp for His at position B10 in insulin makes the molecule more similar to insulin-like growth factor-I, chemically and probably also biologically.
📜 SIMILAR VOLUMES
Vascular smooth muscle cells (SMC) synthesize insulin-like growth factor-I (ILF-I), which is a mitogen for this cell type in vitro. Since IGF binding proteins (IGFBP) modulate IGF bioactivity, we determined which IGFBPs were secreted by porcine SMC. Porcine SMC secreted 34,000 and 24,000 M, forms of
The roles of diabetes mellitus, insulin-like growth factor I and insulin in vascular smooth muscle proliferation in vivo were studied. Proliferation was induced by endothelial injury (balloon catheterization) of rat aorta, and was measured as 3H-thymidine incorporation into DNA. Levels of insulin-li
Several cell types have been shown to secrete insulin-like growth factor binding proteins (IGF-BP) in vitro. Since IGF-BP influences cell responsiveness to IGF, three muscle cell types were investigated to determine if they produced IGF-BP and to identify factors that regulate IGF-BP secretion. Porc
The insulin-like growth factors (IGFs) I and II are present in extracellular fluids associated with specific binding proteins (IGFBPs) that can modify their biologic actions. These studies were undertaken to determine which forms of IGFBP are secreted by endometrial carcinoma (HEC-1 B) and breast ca